

AMENDMENTS TO THE CLAIMS

1-127. (Canceled)

128. (Currently amended) An immunogenic composition for raising an immune response against a coronavirus in a dog, the composition comprising:

a coronavirus having a Spike (S) protein with at least ~~90%~~97% amino acid identity with Canine Respiratory Coronavirus (CRCV) S protein, or a coronavirus S protein having at least ~~90%~~97% amino acid identity with a CRCV S protein, or an immunogenic fragment ~~thereof~~ of a CRCV S protein wherein the fragment is at least 200 amino acid residues in length, or a nucleic acid encoding said coronavirus protein or said immunogenic fragment ~~thereof~~; and a pharmaceutically acceptable carrier or adjuvant.

129. (Currently amended) An immunogenic composition according to Claim 128 wherein the coronavirus S protein is a ~~BCV, HCV, or~~ CRCV protein, or a modification thereof.

130. (Canceled)

131. (Currently amended) An immunogenic composition according to Claim 128 wherein the S protein is selected from the group consisting of:

a coronavirus Spike (S) protein having at least ~~90%~~97% amino acid sequence identity with SEQ ID NO: 4, ~~or a fragment thereof of at least 200 amino acid residues in length~~, said S protein ~~or said fragment~~ comprising at least one of the Canine Respiratory Coronavirus (CRCV)-specific amino acids of SEQ ID NO: 4 selected from the group consisting of 103V, 118V, 166D, 171M, 179K, 192P, 210S, 235H, 267F, 388F, 407M, 436S, 440I, 447I, 501F, 525Y, 528N, 540L, 582K, 608G, 692G, 695S, 757W, 758G, 763Q, 769T, 786P, 792H, 818R, 827P, 828V, 887F, 933D, 977F, 1011T, 1018S, 1063K, 1256L, and 1257M; and

a coronavirus S protein that comprises the amino acid sequence of SEQ ID NO: 4, or a variant thereof with at least 97% amino acid sequence identity with SEQ ID NO: 4, or an immunogenic fragment ~~thereof~~, of SEQ ID NO: 4 wherein the fragment is at least 200 amino acid residues in length;

~~—— a BCV S protein or an immunogenic fragment thereof, wherein the fragment is at least 200 amino acid residues in length; and~~

~~an HCV S protein or an immunogenic fragment thereof, wherein the fragment is at least 200 amino acid residues in length.~~

132-133. (Canceled)

134. (Currently amended) An immunogenic composition according to Claim 128 wherein the coronavirus is ~~selected from the group consisting of BCV, HCV, and CRCV~~, or a modification thereof.

135. (Previously presented) An immunogenic composition according to Claim 128 further comprising a pharmaceutically acceptable adjuvant.

136. (Previously presented) An immunogenic composition according to Claim 128 further comprising any one or more of:

(a) an agent capable of raising an immune response in a dog against canine parainfluenza virus (CPIV);

(b) an agent capable of raising an immune response in a dog against canine adenovirus type 2 (CAV-2);

(c) an agent capable of raising an immune response in a dog against canine herpesvirus (CHV); and

(d) an agent capable of raising an immune response in a dog against *Bordetella bronchiseptica* (*B. bronchiseptica*).

137-143. (Canceled)

144. (Withdrawn) A method of raising an immune response against a coronavirus in a dog, the method comprising administering to the dog an immunogenic composition according to Claim 128.

Application No.: 10/522,513

Filing Date: June 22, 2006

145-163. (Canceled)

164. (Previously presented) The immunogenic composition according to Claim 128, wherein said coronavirus is inactivated.

165. (Previously presented) The immunogenic composition according to Claim 128, wherein said coronavirus is attenuated.

166. (New) The immunogenic composition according to Claim 134, wherein said coronavirus is inactivated.

167. (New) The immunogenic composition according to Claim 134, wherein said coronavirus is attenuated.